共 50 条
- [21] Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Japanese Patients With Type 2 Diabetes MellitusCLINICAL THERAPEUTICS, 2014, 36 (11) : 1606 - 1615Sarashina, AkikoUeki, KohjiroSasaki, TomohiroTanaka, YukoKoiwai, KazukiSakamoto, WataruWoerle, Hans J.Salsali, AfshinBroedl, Uli C.Macha, Sreeraj
- [22] Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 DiabetesDIABETES THERAPY, 2016, 7 (03) : 455 - 471Baron, Kyle T.Macha, SreerajBroedl, Uli C.Nock, ValerieRetlich, SilkeRiggs, Matthew
- [23] Pharmacokinetics and Pharmacodynamics of Vildagliptin in Patients with Type 2 Diabetes MellitusClinical Pharmacokinetics, 2007, 46 : 577 - 588Yan-Ling HeDenise SerraYibin WangJoelle CampestriniGilles-Jacques RiviereCarolyn F. DeaconJens J. HolstSherwyn SchwartzJace C. NielsenMonica Ligueros-Saylan
- [24] Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitusCLINICAL PHARMACOKINETICS, 2007, 46 (07) : 577 - 588He, Yan-LingSerra, DeniseWang, YibinCampestrini, JoelleRiviere, Gilles-JacquesDeacon, Carolyn F.Holst, Jens J.Schwartz, SherwynNielsen, Jace C.Ligueros-Saylan, Monica
- [25] Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteersBRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (01) : 65 - 77Butler, KathleenTeng, Renli
- [26] Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patientsDIABETES OBESITY & METABOLISM, 2009, 11 (08): : 786 - 794Heise, T.Graefe-Mody, E. U.Huettner, S.Ring, A.Trommeshauser, D.Dugi, K. A.
- [27] Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal ImpairmentCLINICAL PHARMACOKINETICS, 2023, 62 (08) : 1093 - 1103Zhao, HengliZhao, ZhiruiHe, KunMi, NianrongLou, KaiDong, XiaolinZhang, WenyuSun, JingfangHu, XinyuPang, ShuguangCheng, HongWen, Qing
- [28] Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal ImpairmentClinical Pharmacokinetics, 2023, 62 : 1093 - 1103Hengli ZhaoZhirui ZhaoKun HeNianrong MiKai LouXiaolin DongWenyu ZhangJingfang SunXinyu HuShuguang PangHong ChengQing Wen
- [29] Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, inChinesepeople with type 2 diabetes mellitusDIABETES OBESITY & METABOLISM, 2020, 22 (12): : 2316 - 2324Li, XiaojiaoZhu, XiaoxueLiu, JingruiLi, QianqianZhang, HongLi, CuiyunWu, MinGao, LeiWen, HeLi, XixiTang, XinranLiu, LiDing, Yanhua
- [30] Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of BI1356 (proposed tradename ONDERO), a dipeptidyl peptidase 4 inhibitor, in Japanese patients with type 2 diabetesDIABETES, 2008, 57 : A158 - A159Kanada, ShigetoWatada, HirotakaHayashi, NaoyukiSarashina, AkikoTaniguchi, AtsushiHorie, YoshhiaraDugi, Klaus A.